Dermata Therapeutics (DRMA)
(Delayed Data from NSDQ)
$2.58 USD
-0.09 (-3.37%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $2.58 0.00 (0.00%) 6:46 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DRMA 2.58 -0.09(-3.37%)
Will DRMA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DRMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DRMA
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
DRMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for DRMA
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Why Is Azitra (AZTR) Stock Down 75% Today?
Why Is Nuzee (NUZE) Stock Up 133% Today?
Why Is Dermata Therapeutics (DRMA) Stock Up 200% Today?